Understanding how NRF2 affects lung squamous cell carcinoma development
Identifying the effects of NRF2 signaling on lung squamous cell carcinoma development
['FUNDING_R21'] · UNIV OF NORTH CAROLINA CHAPEL HILL · NIH-11114732
This study is looking at how a specific protein called NRF2 affects lung squamous cell carcinoma, a type of lung cancer, by using special mice to understand how changes in this protein might lead to cancer growth and make it harder for treatments to work, with the hope of finding better ways to help patients.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF NORTH CAROLINA CHAPEL HILL (nih funded) |
| Locations | 1 site (CHAPEL HILL, UNITED STATES) |
| Trial ID | NIH-11114732 on ClinicalTrials.gov |
What this research studies
This research investigates the role of the NRF2 transcription factor in lung squamous cell carcinoma (LUSC), which is a type of lung cancer. The study uses a genetically-engineered mouse model to explore how mutations in NRF2 contribute to cancer initiation and progression, as well as how they affect the tumor microenvironment. By examining the gene expression and metabolism changes driven by NRF2, the research aims to uncover mechanisms that lead to poor patient outcomes and resistance to existing therapies. This could provide insights into new treatment strategies for patients with LUSC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with lung squamous cell carcinoma or related aerodigestive cancers.
Not a fit: Patients with other types of lung cancer or those not diagnosed with squamous cell carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for lung cancer patients by targeting the NRF2 pathway.
How similar studies have performed: Previous research has shown that targeting similar pathways in cancer has led to promising results, indicating potential for success in this approach.
Where this research is happening
CHAPEL HILL, UNITED STATES
- UNIV OF NORTH CAROLINA CHAPEL HILL — CHAPEL HILL, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WEISSMAN, BERNARD E. — UNIV OF NORTH CAROLINA CHAPEL HILL
- Study coordinator: WEISSMAN, BERNARD E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: aerodigestive squamous cell cancer, cancer cell